ANAFILTAMIG
UNII CLZ7R5K76W
Substance Identification & Data
This profile provides standardized clinical and technical data for Anafiltamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) CLZ7R5K76W.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3009026-69-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
CLZ7R5K76W
3009026-69-8
N/A
Detailed Substance Profile
Preferred Name
ANAFILTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13438
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Anafiltamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Anafiltamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Anafiltamig
Common Names & Synonyms
H-gamma1 heavy chain anti-CD79B Homo sapiens (H) (1-451) hole [VH (Homo sapiens IGHV4-4*07 (83.5%) -(IGHD)-IGHJ3*01 (93.3%), CDR-IMGT [8.7.15] (26-33.51-57.96-110)) (1-121) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v33 CH3 S22, A24, V86 (hole), 10-G1v83 CH3 R115, F116 (CH1 R120>K (218) (122-219) (hinge 1-15 (220-234), CH2 L1.3>A(238), L1.2>A (239), D27>S (269) (235-344), CH3 E12 (360), M14 (362), T22>S (370), L24>A (372), Y86>V (411), H115>R (439), Y116>F (440) (345-449), CHS (450-451)) (122-451)],(224-220')-disulfide with L-kappa light chain anti-CD79B Homo sapiens (L') (1'-220') [V-KAPPA (Homo sapiens IGKV2-40*01 (89.1%) -IGKJ1*01 (100%), CDR-IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'), V101 (197')) (114'-220')]; scFvkh-G1(h-CH2-CH3)-20mer-scFvkh heavy chain anti-CD3E and anti-MS4A1 (H'') (1''-747'') knob [scFvkh anti-CD3E humanized (1''-247'')[V-KAPPA (Homo sapiens IGKV3-11*02 (81.1%) -IGKJ4*01 (100%), CDR-IMGT [5.3.9] (27''-31''.49''-51''.88''-96'')) (1''-106'') -20-mer (GGSEGKSSGSGSESKSTGGS) linker (107''-126'') -VH (Homo sapiens IGHV1-46*01 (83.5%) -(IGHD)-IGHJ4*01(92.9%), CDR-IMGT [8.8.14] (152''-159''.177''-184''.223''-236'')) (127''-247'')] -G1(h-CH2-CH3) (248''-479'') [Homo sapiensIGHG1*03v, nG1m1 CH3 E12, M14, 15-G1v37 h S5, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v32 CH3 W22 (knob) (hinge 1-15 C5>S(252'') (248''-262''), CH2 L1.3>A (266''), L1.2>A (267''), D27>S (297'') (263''-372''), CH3 E12 (388''), M14 (390''), T22>W (398'') (373''-477''), CHS (478''-479''))] -20-mer tetrakis(tetraglycyl-seryl) linker (480''-499'') -scFvkh anti-MS4A1 humanized (500''-747'') [V-KAPPA (Homo sapiens IGKV3-11*01 (91.1%) -IGKJ4*01 (100%), CDR-IMGT [5.3.9] (526''-530''.548''-550''.587''-595'')) (500''-605'') -20-mer (GGSEGKSSGSGSESKSTGGS) linker (606''-625'') -VH (Homo sapiens IGHV1-69*01 (88.8%) -IGHD -IGHJ6*05 (92.3%) A127>S (746''), CDR-IMGT [8.8.15] (651''-658''.676''-683''.722''-736'')) (626''-747'')]]; dimer (230-258'':233-261'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
anafiltamig [INN]
immunoglobulin (H-gamma1_L-kappa)_(scFvkh-G1(h-CH2-CH3)-20mer-scFvkh), anti-[Homo sapiens CD79B (immunoglobulin-associated coreceptor CD79 beta), anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)] andanti-[Homo sapiens MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], Homo sapiens and humanized monoclonal antibody; trispecific, trivalent
